Cormorant Asset Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Cormorant Asset Management’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-130,000	Closed	-$2.41M	–	116
2021 Q1	$2.41M	Buy	+130,000	New	+$2.66M	0.05%	107
2019 Q2	–	Sell	-270,000	Closed	-$4.88M	–	76
2019 Q1	$4.88M	Sell	270,000 -561,000	-68%	-$10.8M	0.33%	49
2018 Q4	$23.3M	Hold	831,000	–	–	1.9%	16
2018 Q3	$21.2M	Hold	831,000	–	–	1.38%	28
2018 Q2	$13.8M	Buy	+831,000	New	+$15M	1.02%	30

Other funds holding KNSA

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Cormorant Asset Management's KNSA Position: Q2 2021 in Review

Cormorant Asset Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2021, closing a stake of 130,000 shares — an estimated $2.41M sold.

Cormorant Asset Management first reported a position in KNSA in Q2 2018 and held it in 5 quarters. The position peaked at $23.3M in Q4 2018. 102 funds tracked by Wall St. Rank hold KNSA as of Q2 2021.

Cormorant Asset Management reported no remaining Kiniksa Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Cormorant Asset Management sold 130,000 Kiniksa Pharmaceuticals shares in Q2 2021, an estimated $2.41M.
Cormorant Asset Management first reported a position in Kiniksa Pharmaceuticals in Q2 2018 and held it in 5 quarters.
Cormorant Asset Management's Kiniksa Pharmaceuticals position peaked at $23.3M in Q4 2018.
102 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2021.

Based on Cormorant Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.